Sign in
TerminatedNo phase

Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

Key facts

Who runs it
Indiana University
Where
Indianapolis and Portland, United StatesSee the 3 sites
Trial code
Status
Terminated
People taking part
18 people enrolled
Started
12 Dec 2019
Ended
20 Feb 2024
Type of study
Interventional
Treatments tested
  • Reduced Dose SRS
Record updated
13 February 2025
Why it stopped
trial stopped due to low accrual

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Brain MRI-confirmed 1-10 solid tumor brain metastases
  • Biopsy-confirmed primary malignancy
  • ds-GPA estimated median survival of at least 6 months, for histologies not included in the ds-GPA, publications or noted online at brainmetgpa.com, the PI will use either published or validated data or their best clinical judgment to determine the patient's expected survival
  • Stereotactic radiosurgery candidate per treating Radiation Oncologist
  • ≥ 18 years old at the time of informed consent
  • Ability to provide written informed consent and HIPAA (Health Insurance Portability and Accountability Act) authorization
  • ALC > 800/ul (Ku et al., 2010)
  • Patients currently on cytotoxic chemotherapy are eligible
  • Patients receiving ICI up to 30 days prior to delivery of SRS are eligible
  • Patients having undergone operative resection for metastatic brain disease within 30 days of immune checkpoint inhibitor (ICI) administration are eligible

Who cannot take part

  • Previous whole brain radiation therapy
  • For Cohort 1: Previous stereotactic radiosurgery where the 50% isodose line overlaps with current treatment field
  • For Cohort 2: Patients whose treatment will have a dose overlap within the target from prior treatments of 20% or greater
  • Already receiving chronic dexamethasone (chronic = > 2 weeks) prior to SRS
  • Not a radiosurgical candidate per Radiation Oncology discretion
  • Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and/or interfere with follow-up
  • Total volume of metastatic disease more than 30 cubic centimeters
  • Existing autoimmune disease
  • Patients who have an unknown primary cancer
  • Histology not amenable for SRS (i.e. lymphoma). (Small Cell Lung Cancer IS amenable.)
  • Patients unable to receive MRI Brain
  • Patients with more than 10 brain metastases on MRI Brain imaging
  • Any lesion > 4 centimeter maximum diameter

Where in United States

  • Indiana University Health HospitalIndianapolis, United States
  • Indiana University Methodist HospitalIndianapolis, United States
  • Oregon Health and SciencesPortland, United States

About the trial

What the trial wants to find out

This study will evaluate the rate of radiation necrosis following treatment with immune checkpoint inhibitor (ICI) treatment and radiation therapy in subjects with metastatic brain cancer. Subjects will be treated with the standard of care immunotherapy followed by radiation therapy via stereotactic radiosurgery at a reduced dose.

The group in the trial

  • Reduced Dose Stereotactic RadiosurgeryTreatment being tested

    Subjects will receive one stereotactic radiosurgery (SRS) treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 3, 6, 9, and 12 months post SRS treatment

    Treatment: Reduced Dose SRS

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
13 February 2025